bluuebunny/crossref_metadata_2025_split huggingface dataset:
Environmental Impact of Ineffective Antibiotic Disposal: Strategies and Remedial Pathways: A Comprehensive Review
Authors: Geetha Rajendran 
Published: January 2025

ABSTRACTThe discovery and use of antibiotics revolutionized medicine, significantly reducing mortality from infectious diseases. However, widespread and often indiscriminate antibiotic use has led to environmental contamination, fostering antibiotic‐resistant bacteria and posing serious public health threats. This review explores the primary sources of environmental contamination, including improper disposal by households, healthcare institutions, agriculture, and pharmaceutical manufacturing. These sources contribute to the persistence of antibiotic residues and the proliferation of antibiotic resistance genes (ARGs) in natural ecosystems. The environmental presence of antibiotics disrupts microbial communities, impacting ecosystem functions such as nutrient cycling and biodiversity. Various remediation strategies exist to address this issue, ranging from physicochemical methods like adsorption and advanced oxidation processes (AOPs) to bioremediation and electrochemical techniques. Bioremediation employs naturally occurring or engineered microorganisms to degrade or detoxify antibiotics, while electrochemical processes, including microbial electrochemical systems (MES) and cathodic degradation, use electrical currents to break down antibiotic molecules. These approaches have demonstrated effectiveness in different environments, but challenges remain in scaling up their application. Hybrid methods, integrating bioremediation with electrochemical treatments, show promise for enhanced contaminant removal, making them feasible for addressing complex contamination scenarios. Future research should focus on optimizing these methods for broader application, promoting a sustainable solution to mitigate the environmental impact of antibiotics and safeguard public health.
A Holistic Catchment‐Scale Framework to Guide Flood and Drought Mitigation Towards Improved Biodiversity Conservation and Human Wellbeing
Authors: Haubrock Phillip J. , Stubbington Rachel , Fohrer Nicola , Hollert Henner , Jähnig Sonja C. , Merz Bruno , Pahl‐Wostl Claudia , Schüttrumpf Holger , Tetzlaff Doerthe , Wesche Karsten , Tockner Klement , Haase Peter 
Published: January 2025

ABSTRACTAs climatic extremity intensifies, a fundamental rethink is needed to promote the sustainable use of freshwater resources. Both floods and droughts, including water scarcity, are exacerbating declines in river biodiversity and ecosystem services, with consequences for both people and nature. Although this is a global challenge, densely populated regions such as Europe, East Asia and North‐America, as well as the regions most affected by climate change, are particularly vulnerable. To date mitigation measures have mainly focused on individual, local‐scale targets, often neglecting hydrological connectivity within catchments and interactions among hydrology, biodiversity, climate change and human wellbeing. A comprehensive approach is needed to improve water infiltration, retention and groundwater recharge, thereby mitigating the impacts of heavy rainfall and floods as well as droughts and water scarcity. We propose a holistic catchment‐scale framework that combines mitigation measures including conventional civil engineering methods, nature‐based solutions and biodiversity conservation actions. This framework integrates legislation, substantial funding and a governance structure that transcends administrative and discipline boundaries, enabling coordinated actions across multiple spatial and temporal scales. It necessitates the collaboration of local and regional stakeholders including citizens, scientists and practitioners. A holistic vision for the sustainable management of freshwater resources could have synergistic effects that support biodiversity and mitigate climate change within functional ecosystems that deliver benefits to people.
A Pipeline to Explore Transient Signals in GNSS Data: A Preliminary Approach Applied to the Cascadia Subduction Margin
Authors: Garcia Cristian , Männel Benjamin , Glaser Susanne , Bedford Jonathan 
Published: January 2025

AbstractThroughout the earthquake cycling at fault zones, Earth’s crust undergoes deformations. GNSS coordinate time series record linear tectonic motion, seismic displacements, postseismic decays, and periodic signatures such as non-tidal loading. Any additional motions can be classed as transient tectonic signals, i.e., unexpected accelerations with respect to the standard trajectory model. As the number of permanent stations increases and as time series grow, we are increasingly able to recognise transient tectonic signals. Since some of these suspected tectonic transients have subtle magnitudes or sometimes unusual spatiotemporal features, we need to develop methods for determining which transients are artifacts and which are of tectonic origin.Here, we investigate the impact of certain GNSS processing choices and how they affect the appearance of transients in the GNSS displacement time series solutions. In this study, we choose data from Cascadia, a region for which the occurrence of transient signals in the GNSS time series is well known. We processed data based from 189 selected stations in network mode for the time span 2015 to 2019. After producing coordinate time series, we then built a pipeline to isolate processing artifacts and tectonic transients, using the regression model-based algorithm known as GrAtSiD (Greedy Automatic Signal Decomposition).The residuals of GNSS observations show that most sites have a precision of 5 mm to 10 mm. Using the GrAtSiD algorithm, we detected transient signals with velocities exceeding 0.3 mm/day near the ALBH station.
New Rat Model Mimicking Sacrocolpopexy for POP Treatment and Biomaterials Testing via Unilateral Presacral Suspension
Authors: Lu Chenxi , Zhou Jun , Kong Qingyu , Wang Lulu , Ni Wei , Xiao Zhen 
Published: January 2025

Abstract

Introduction and Hypothesis
Pelvic organ prolapse (POP) impacts women’s health and quality of life. Post-surgery complications can be severe. This study uses rat models to replicate sacrocolpopexy and test materials for pelvic support, verifying the 4-week postoperative mortality rate, the mechanical properties of the mesh tissue, and the collagen content.

Methods
Twenty-one 12-week-old female Wistar rats were used. Eighteen rats were subjected to POP induction by cervical suction and constant traction. One week after prolapse modeling, 18 prolapsed rats underwent unilateral presacral suspension (UPS) surgery with polycaprolactone (PCL) scaffolds, decellularized porcine small intestinal submucosa (SIS) scaffolds, or polypropylene (PP) meshes (n = 6 each). UPS rats were compared with normal rats (n = 3). After 4 weeks, conditions and mortality were recorded. The rats were then euthanized for biomechanical testing and collagen analysis. Ultimate load (N) was defined as the highest load before the failure of the target sample.

Results
The UPS procedure requires 42.9 ± 4.5 min with no complications or deaths over 4 weeks. SIS was the stiffest mesh (14.53 ± 0.86 N), followed by PP (8.43 ± 0.40 N), and PCL was the least stiff (0.66 ± 0.05 N). After 4 weeks, the ultimate load of the PCL complex increased to 1.71 ± 0.41 N (p = 0.0120), but showed no significant difference from parametrial fascia (1.25 ± 0.85 N) and uterosacral ligament (0.66 ± 0.41 N). The ultimate load of the SIS complex decreased to 5.99 ± 0.37 N, still higher than native tissue. The PP complex’s ultimate load (10.02 ± 1.80 N) showed no significant difference from PP alone. The collagen ratio of the PCL complex (48.11 ± 9.88%) was closest to that of the uterosacral ligament (36.66 ± 11.64%), whereas SIS and PP complexes had significantly higher collagen ratios than USL.

Conclusions
Unilateral presacral suspension mimics classical surgery for human POP in rats. First, this procedure can investigate the mechanical properties of pelvic floor tissues at the cellular level after correcting POP. Second, it can be used to validate new materials for the surgical treatment of POP, including but not limited to foreign body reactions with surrounding tissues, absorption time, etc. Third, it can be used to study the biological mechanisms of mesh exposure.
Development and validation of an indirect competitive lateral flow immunoassay for the detection of acetaminophen (paracetamol) in bovine urine
Authors: Sasse Samantha , Geballa-Koukoula Ariadni , Bovee Toine F. H. 
Published: January 2025

Abstract
Paracetamol (PCM) is a commonly used analgesic and antipyretic agent for humans worldwide. However, PCM overdoses or overuse can cause health issues, such as hepatoxicity. As PCM is also used for the treatment of farm animals, it is essential to monitor these residues in animal-derived matrices at risk-based sites in order to minimize the intake of PCM through the food chain. In the present study, we have developed a novel carbon nanoparticle (CNP)-based indirect competitive lateral flow immunoassay (icLFIA) for the rapid detection of PCM in bovine urine. The developed icLFIA can detect PCM residues within 10 min, and its performance was validated according to Commission Implementing Regulation (EU) 2021/808, i.e., determination of the detection capability (CCβ), specificity, robustness, and stability. The CCβ of the icLFIA for PCM in bovine urine is 5 mg/L and the icLFIA is proven to be selective and specific towards PCM in bovine urine, as no matrix interference and cross-reactivity were observed, except for high concentrations of orthocetamol. The icLFIA for PCM in bovine urine is robust to (small) variations in reading time, but it remains necessary to strictly use a dilution ratio of running buffer/bovine urine of 80/20. Moreover, the produced icLFIAs are stable for at least 56 days under the stored conditions. In conclusion, the developed and validated icLFIA provides a rapid and cost-effective method for on-site monitoring of PCM abuse in cattle.
Pharmacogenetics of opioid medications for relief of labor pain and post-cesarean pain: a systematic review and meta-analysis
Authors: Giacon Martina , Cargnin Sarah , Talmon Maria , Terrazzino Salvatore 
Published: January 2025

Abstract

Objective
Several studies have attempted to identify genetic determinants of clinical response to opioids administered during labor or after cesarean section. However, their results were often contrasting. A systematic review and meta-analysis was conducted to quantitatively assess the association between gene polymorphisms and clinical outcomes of opioid administration in the treatment of labor pain and post-cesarean pain.

Methods
A comprehensive search was performed up to December 2023 using PubMed, Web of Knowledge, Cochrane Library, and OpenGrey databases. The clinical endpoints of interest were pain score after opioid treatment, total opioid consumption, patient’s analgesic satisfaction, and incidence of opioid side effects. Random-effects meta-analyses were conducted when data were available in at least three studies.

Results
Twenty-six studies enrolling 7765 patients were included in the systematic review. Overall, a total of 12 candidate polymorphic genes (OPRM1, COMT, CYP2D6, CYP3A4, ABCB1, ABCC3, UGT2B7, CGRP, OPRK1, OPRD1, KCNJ6, KCNJ9) were considered by the included studies, among which the most investigated variant was OPRM1 rs1799971. Overall pooled results indicated that individuals carrying the G allele of OPRM1 rs1799971 required higher opioid doses for pain management in comparison to rs1799971 AA subjects (standardized mean difference: 0.26; 95% CI: 0.09–0.44; P = 0.003). Such an association was confirmed in the subgroups of patients with labor pain and post-cesarean pain.

Conclusion
The present meta-analysis provides strong evidence of an association between OPRM1 rs1799971 and opioid dose requirement for relief of labor pain or post-cesarean pain. However, given the insufficient evidence for other polymorphic gene variants, large studies are still needed to investigate the impact of genetic variability on the efficacy and safety of opioid medications for relief of labor pain and post-cesarean pain (INPLASY Registration No. 202410040).
The Amphibian Major Histocompatibility Complex—A Review and Future Outlook
Authors: Sabino-Pinto Joana , Maan Martine E. 
Published: January 2025

Abstract
The major histocompatibility complex (MHC) is a cluster of functionally related genes encoding proteins which, among other functions, mediate immune system activation. While the MHC of many vertebrates has been extensively studied, less is known about the amphibian MHC. This represents an important knowledge gap because amphibians mark the evolutionary transition from an aquatic to a terrestrial lifestyle and often maintain a biphasic lifestyle. Hence, they tend to be exposed to both aquatic and terrestrial pathogen communities, providing opportunities to gain fundamental insights into how the immune system responds to different environmental challenges. Moreover, amphibians are globally threatened by invasive pathogens and the MHC may play a role in combating population decline. In this review, we summarize the current state of knowledge regarding the amphibian MHC and identify the major differences with other vertebrates. We also review how the number of MHC gene copies varies across amphibian groups and how MHC-based variation relates to amphibian ontogeny, behaviour, disease, and phylogeography. We conclude by identifying knowledge gaps and proposing priorities for future research.
Anxiety of microbially synthesized Fe3O4-SPIONs on embryonic/larval ontogeny in red tilapia (Oreochromis sp.)
Authors: Abouelkheir Samia S. , Mourad Mona M. 
Published: January 2025

Abstract
Iron oxide nanoparticles, recognized for their superparamagnetic properties, are promising for future healthcare therapies. However, their extensive use in medicine and electronics contributes to their discharge into our environments, highlighting the need for further research on their cellular damage effects on aquatic organisms. While the detrimental properties of other compounds have been stated in the early-life stages of fish, the cytotoxic consequences of superparamagnetic iron oxide nanoparticles (SPIONs) in these stages are still unexplored. Therefore, using the red tilapia (Oreochromis sp.) as a model organism, this study is the first to talk about the subtle cellular alterations caused by biologically induced biomineralized Fe3O4-SPIONs by Bacillus sp. in the early-life stages. Once the red tilapia eggs were fertilized, they were challenged to different doses of SPIONs (0, 5, 10, 15, and 30 mg/l), and their tenfold increases (50, 100, 150, and 300 mg/l) for 72 h. The hatching rate, malformation rate, body length, and deformities of the larvae were all studied. Our research showed that iron oxide nanoparticles were harmful to the early stages of life in red tilapia embryos and larvae. They slowed hatching delay, a decrease in survival rate, an increase in heart rate, bleeding, arrested development, and membrane damage and changed the axis’s physiological structure. Additionally, results indicated numerous deformities of red tilapia larvae, with lordosis, kyphosis, and scoliosis once subjected to 50 and 150 mg/l of SPIONs concentrations, respectively. This study could assist us in recognizing the risk and evaluating the disrupting potential of nanoparticles. The key objective of this inquiry is to describe the existing features of the produced magnetite SPIONs (29.44 g/l) including their morphological, chemical, and magnetic characteristics. Illustrate their current role in medicinal applications and aquatic organisms by studying in vivo cytotoxic effects to motivate the development of enhanced SPIONs systems. As a recommendation, more research is needed to completely understand how various exposure endpoints of SPIONs disturb the bodies of red tilapia in the early stages.

Key points
• Biogenic SPIONs: a material of the future.
• Characterization is essential to assess the functional properties of the produced SPIONs.
• Fe3O4-SPIONs’ impact on the red tilapia ontogeny.

Graphical abstract
Can mindfulness have long-term impact on patients with fibromyalgia? A two-year prospective follow-up study of a mindfulness-based intervention
Authors: Zangi Heidi A. , Haugmark Trond , Provan Sella Aarrestad 
Published: January 2025

Abstract
To examine changes in symptoms and health status in patients with fibromyalgia (FM) 24 months after participating in the mindfulness-based group-program, the Vitality Training (VTP), followed by physical exercise counselling. Seventy-six participants, mean age (range) 43 (26–52), females 69 (91%), diagnosed with FM according to the ACR 2011-criteria received the VTP in a previous randomised controlled trial. Control group participants could receive the VTP after a 12-month observation period, therefore only data from the intervention group were analysed in the present study. Self-reported data were collected electronically at baseline, 3, 12 and 24 months. Outcomes were patient global impression of change (PGIC), FM-severity, i.e. widespread pain (WPI) and symptom severity (SSS), pain, fatigue, sleep quality, psychological distress, motivation and barriers for physical activity, mindfulness and work participation. Trends across time-points were analysed using mixed models for repeated measurements. At 24-months, 48 (56.5%) participants responded, 94% female, median (range) age 46 (28–54), symptom duration 12 (5–33) years. Seven participants reported much/very much better on the PGIC; 21 (44%) reported no change/minimal improvement. Improvements were observed in WPI (-1.9, ES 0.4), SSS (-1.2, ES 0.6), fatigue (-0.8, p =.014) and self-efficacy for physical activity (1.4, ES 0.4). There was a significant trend of reduced WPI, SSS, pain and fatigue across the four time-points, but no additional improvements from 12 to 24-month follow-up. Participants who had completed the VTP demonstrated small to moderate improvements in symptom burden and FM-severity from baseline to 24-month follow-up. Trial registration number: ISRCTN96836577 https://doi.org/10.1186/ISRCTN96836577, prospectively registered 12.07.2016.
Combined transrectal ultrasound and radiomics model for evaluating the therapeutic effects of neoadjuvant chemoradiotherapy in locally advanced rectal cancer
Authors: Abuliezi Dilimire , She Yufen , Liao Zhongfan , Luo Yuan , Yang Yin , Huang Qin , Tao Anqi , Zhuang Hua 
Published: January 2025

Abstract
Purpose
This study aimed to explore a combined transrectal ultrasound (TRUS) and radiomics model for predicting tumor regression grade (TRG) after neoadjuvant chemoradiotherapy (NCRT) in patients with locally advanced rectal cancer (LARC).

Methods
Among 190 patients with LARC, 53 belonged to GRG and 137 to PRG. Eight TRUS parameters were identified as statistically significant (P < 0.05) for distinguishing between the groups, including PSVpre, LDpost, TDpost, CEUS-IGpost, LD change rate, TD change rate, RI change rate, and CEUS-IG downgrade. The accuracies of these individual parameters in predicting TRG were 0.42, 0.62, 0.56, 0.68, 0.67, 0.70, 0.63, and 0.71, respectively. The AUC values were 0.596, 0.597, 0.630, 0.752, 0.686, 0.660, 0.650, and 0.666, respectively. The multi-parameter ultrasonic logistic regression (MPU-LR) model achieved an accuracy of 0.816 and an AUC of 0.851 (95% CI: [0.792–0.909]). The optimal pre- and post-treatment radiomics models were RF (Mean-PCA-RFE-6) and AE (Zscore-PCA-RFE-12), with accuracies of 0.563 and 0.596 and AUCs of 0.601 (95% CI: [0.561–0.641]) and 0.662 (95% CI: [0.630–0.694]), respectively. The combined model (US-RADpre-RADpost) showed the highest predictive power with accuracy and AUC of 0.863 and 0.913.

Conclusions
The combined model based on TRUS and radiomics demonstrated remarkable predictive capability for TRG after NCRT. It serves as a precision tool for assessing NCRT response in patients with LARC, impacting treatment strategies.
Cost effectiveness of different treatment strategies with natalizumab for pregnant women with multiple sclerosis
Authors: Walbaum Magdalena , Madhukar Anushka , Dobson Ruth , Cyhlarova Eva , Castro-Aldrete Laura , Santuccione Chadha Antonella , Knapp Martin 
Published: January 2025

Abstract

Background
The management of multiple sclerosis (MS) during pregnancy poses significant challenges. This study aimed to evaluate the cost-effectiveness of three natalizumab treatment strategies during pregnancy from the UK healthcare system’s perspective.

Methods
A Markov model was developed to assess the health outcomes and costs associated with three treatment strategies: continuous natalizumab treatment throughout pregnancy, treatment until the first trimester followed by discontinuation, and discontinuation at conception with resumption post-pregnancy. The model incorporated data on relapse rates, disability progression, costs and quality-adjusted life years (QALYs). Sensitivity analyses were conducted.

Results
Continuing natalizumab throughout pregnancy was the most cost-effective strategy, yielding the highest incremental QALY gains and the lowest incremental cost per QALY (£1713 per QALY), with a net monetary benefit of £743. The sensitivity analyses confirmed the robustness of these findings and the use of generic or biosimilar forms of natalizumab further reinforced the cost-effectiveness of continuous treatment, with the biosimilar option proving cost-saving.

Conclusion
Continuing natalizumab treatment throughout pregnancy is the most cost-effective approach for managing MS in pregnant women. These findings should inform clinical guidelines and support healthcare providers and women with MS planning their family in making evidence-based decisions to improve the management of MS during pregnancy.
Challenges in multinational rare disease clinical studies during COVID-19: regulatory assessment of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease
Authors: Schoser Benedikt , Attarian Shahram , Graham Ryan , Holdbrook Fred , Goldman Mitchell , Díaz-Manera Jordi ,   The ATB200-03 study group
Published: January 2025

Abstract
PROPEL (ATB200-03; NCT03729362) compared the efficacy and safety of cipaglucosidase alfa plus miglustat (cipa + mig), a two-component therapy for late-onset Pompe disease (LOPD), versus alglucosidase alfa plus placebo (alg + pbo). The primary endpoint was change in 6-min walk distance (6MWD) from baseline to week 52. During PROPEL, COVID-19 interrupted some planned study visits and assessment windows, leading to delayed visits, make-up assessments for patients who missed ≥ 3 successive infusions before planned assessments at weeks 38 and 52, and some advanced visits (end-of-study/early-termination visits). These were remapped to the respective planned visits. To evaluate if remapping may have overestimated treatment effects, we conducted post hoc analyses using a mixed-effect model for repeated measures based on actual time points of assessments. In this post hoc analysis, estimated mean treatment difference between cipa + mig and alg + pbo for change from baseline to week 52 in 6MWD was 11.7 m (95% confidence interval [CI] − 1.0 to 24.4; p = 0.072). In the original published analyses, between-group difference using last observation carried forward was 13.6 m (95% CI − 2.8 to 29.9; p = 0.071 [p value from separate non-parametric analysis of covariance]). Both statistical analysis approaches led to similar results and consistent conclusions, confirming the efficacy of cipa + mig for adults with LOPD. NCT03729362; trial start date: December 4, 2018.
Trial registration number